sodium nitrite Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Nitrite, and when can generic versions of Sodium Nitrite launch?
Sodium Nitrite is a drug marketed by Hope Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-eight patent family members in fourteen countries.
The generic ingredient in SODIUM NITRITE is sodium nitrite. There are one thousand four hundred and seventy-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium nitrite profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Nitrite
A generic version of sodium nitrite was approved as sodium nitrite by HOPE PHARMS on February 14th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for sodium nitrite?
- What are the global sales for sodium nitrite?
- What is Average Wholesale Price for sodium nitrite?
Summary for sodium nitrite
International Patents: | 28 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 58 |
Patent Applications: | 1,397 |
What excipients (inactive ingredients) are in sodium nitrite? | sodium nitrite excipients list |
DailyMed Link: | sodium nitrite at DailyMed |
Recent Clinical Trials for sodium nitrite
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Alabama at Birmingham | Early Phase 1 |
University of Alabama at Birmingham | Phase 1 |
National Institutes of Health (NIH) | Phase 1 |
Medical Subject Heading (MeSH) Categories for sodium nitrite
Anatomical Therapeutic Chemical (ATC) Classes for sodium nitrite
US Patents and Regulatory Information for sodium nitrite
sodium nitrite is protected by three US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hope Pharms | SODIUM NITRITE | sodium nitrite | SOLUTION;INTRAVENOUS | 203922-001 | Feb 14, 2012 | RX | Yes | Yes | 9,687,506 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Hope Pharms | SODIUM NITRITE | sodium nitrite | SOLUTION;INTRAVENOUS | 203922-001 | Feb 14, 2012 | RX | Yes | Yes | 8,568,793 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for sodium nitrite
See the table below for patents covering sodium nitrite around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3862007 | COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS) | ⤷ Subscribe |
Canada | 2752129 | COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS) | ⤷ Subscribe |
Hungary | E055250 | ⤷ Subscribe | |
European Patent Office | 3569237 | COMPOSITIONS PHARMACEUTIQUES CONTENANT DU NITRITE DE SODIUM (SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for sodium nitrite
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2203431 | CA 2015 00014 | Denmark | ⤷ Subscribe | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115 |
2465580 | SPC/GB21/030 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
0579826 | SPC/GB02/042 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422 |
0145340 | 99C0005 | Belgium | ⤷ Subscribe | PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Sodium nitrite Market Analysis and Financial Projection Experimental
More… ↓